

Serial No.: 10/542,214
Case No.: 21317YP
Page No.: 22

REMARKS

The Office Action dated March 14, 2007, has been carefully considered. The Applicants respectfully request reconsideration of the application in view of the foregoing amendments and the following remarks.

Claims 54-56 have been cancelled without prejudice. Claims 1-51 and 53 are now pending in the application following the above amendments. Claims 1-51 are allowed.

Claims 53-56 are rejected under 35 USC §112, first paragraph, as failing to comply with the enablement requirement.

Claims 54-56 have been cancelled without prejudice. Support for inhibition of DP-IV enzyme activity is provided below for six specific examples disclosed in the application:

<u>Example No.</u>	<u>DP-IV inhibition (IC50-nanomolar)</u>
18	26
19	13
20	1.5
35	9.9


Support for the utility of DP-IV inhibitors for the treatment of Type 2 diabetes is found in references Nos. 41-43, 45, 48-50 cited in the Information Disclosure Statement.

In light of this amendment and argument, the Applicants respectfully request withdrawal of the section 112, first paragraph, rejection.

Serial No.: 10/542,214
Case No.: 21317YP
Page No.: 23

The Applicants believe that all of the objections have been overcome by amendment, and they therefore earnestly solicit an early Notice of Allowance.

Respectfully submitted,

By 
Philippe L. Durette
Reg. No. 35,125
Attorney for Applicants
Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-4568

Date: March 29, 2007